Sartorius: Aiming for double-digit growth starting in 2027, seeks to revolutionize cell therapy with the Eveo platform. Is the correction that began in 2022 coming to an end?
Reading Time: 2 minutes
SARTORIUS VZ has definitively left the consolidation phase behind after the pandemic years. CEO Dr. Michael Grosse presents a strategy at today's Capital Markets Day that focuses on maximum efficiency and technological dominance. Sartorius provides solutions for the most pressing challenges in the biopharma world: scalability and costs. Is the Eveo platform transforming cell therapy away from a niche? A future growth driver lies in process intensification. The newly introduced Eveo Cell Therapy Platform directly addresses the structural bottlenecks...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
